LRP/LR Receptor Modulation for Telomere Length and Senescence Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds and methods to treat and prevent telomere-related diseases and medical conditions, particularly cancer and cellular ageing, as existing treatments are inadequate in addressing these conditions effectively.
Innovation Solution
The use of a 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) or its fragments, which are administered to increase hTERT levels and telomerase activity, thereby extending telomere length and impeding cellular senescence, is proposed. This involves formulating LRP/LR into pharmaceutical compositions for various administration routes and employing methods such as transfection to upregulate LRP/LR levels in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for telomere-related diseases, then treatment is provided, but the treatments are inadequate in addressing cancer and cellular ageing effectively
Solution Approach 1:
The patent uses small molecule compounds that bind to hTERT to modulate telomerase activity through parameter changes in molecular interaction, achieving both anti-cancer effects by inhibiting telomerase in tumor cells and pro-ageing effects by maintaining telomerase function in normal cells
Solution Approach 2:
The invention provides a universal therapeutic approach using compounds that can treat multiple telomere-related diseases including cancer, cellular ageing, and age-related conditions through a common mechanism of hTERT binding, achieving versatility across different disease states
2Duration of action of stationary object
If hTERT levels and telomerase activity are increased to extend telomere length, then cellular senescence is impeded, but cancer risk may increase due to uncontrolled cell proliferation
Solution Approach 1:
The patent applies local quality by having different compounds or dosages affect different cell types differently - using hTERT-binding compounds that can selectively inhibit telomerase in cancer cells while preserving function in normal cells, or using LRP/LR fragments that specifically target senescent cells for removal
Solution Approach 2:
The invention uses LRP/LR as an intermediary mechanism to selectively clear senescent cells through immune system activation, while using small molecule compounds as intermediaries to bind hTERT and modulate telomerase activity with selective toxicity toward cancer cells
Data Source
AI summary
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cancer and cellular ageing. Particularly, herein is disclosed 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in the treatment and/or prevention of cellular ageing.